Skip to main content

Table 2 Summary of non-cancer mammalian pathologies in which YAP/TAZ proteins are involved

From: The Hippo pathway in disease and therapy: cancer and beyond

Tissue Protein Model Pathology References
Liver YAP Mouse models of inducible active YAP1 in the liver Increase in liver size [64, 65]
Heart YAP/TAZ SCA-1-/- human cardiac progenitor cell line Infarct [66]
Cardiac-specific YAP or TAZ knockout mice. Mouse model of inducible active YAP1 in the heart Loss of function results in impaired neonatal heart regeneration and lethal cardiomyopathy. Activated YAP enhances cardiac regeneration and improves function of ischemic hearts [67]
YAP Mouse models of arrhythmogenic cardiomyopathy and human samples Arrhythmogenic Cardiomyopathy [47]
Mouse models of cardiomyocyte-specific homozygous inactivation of YAP in the postnatal heart Increased myocyte apoptosis and fibrosis, dilated cardiomyopathy, and premature death. [68]
Muscle YAP Mouse models of inducible active YAP in the skeletal muscle cells Loss of body weight, gait impairments and kyphosis. Skeletal muscle atrophy. [69]
Brain YAP/TAZ Rat model of chronic constriction sciatic nerve injury Neuropathic pain [70]
YAP/TAZ Mammalian cell lines Alzheimer’s disease [71]
Pancreas YAP MST1/2 mutant conditional mouse Reduction of pancreatic mass, exocrine pancreas disorganization and pancreatitis-like autodigestion [54, 55]
Mouse models of inducible active YAP1 in the pancreas Pancreas increased in total size and acinar cells showed penetrant ductal metaplasia [64]
Skin YAP/TAZ Mice model of wound healing Wound healing [72]
YAP Mouse models of inducible active YAP1 in the skin Thickening of the epidermis and increased number of proliferating cells [64]
Eye YAP/TAZ Primary human trabecular meshwork cells Glaucoma [73]
Ovary YAP/TAZ Mouse model of ovarian fragmentation, ovarian explant and follicle cultures. Primary ovarian insufficiency patients Primary ovarian insufficiency and polycystic ovarian syndrome [74]